Pulmonology

The therapy reduces death by 35% in patients with respiratory complications.

What risks of severity do patients face with viral infection?

A look at how the rare pulmonary disease field of research has been limited.

A look at the appropriate referral and promising agents for care of the rare pulmonary disease.

Greg Cosgrove, MD, explains how the respiratory condition can be overlooked by patients and clinicians.

A new Canadian Thoracic Society guidance sets recommendations for continued or halted use of inhaled steroids, nebulizers, biologics, and more.

The biologic has now shown significant efficacy in treating 4 different atopic or type 2 inflammatory diseases.

How clinical data for the interleukin-targeting class will begin to dictate more treatement decisions and research progression.

Asthmatic infants often suffer from other comorbidities throughout their lives.

Blood eosinophil count, exacerbation rate, and time to exacerbation were all bettered among patients who sustained therapy versus those who discontinued.

In an abstract presenting during the ATS conference, investigators find infants with asthma are surprisingly older on the epigentic clock.

New findings from ATS show the residual effects of vaping-associated lung distress.

The lead PATHWAY investigator explains the intent and outcomes from the most recent phase 2B findings.

A discussion with a study author on promising new findings for the combination inhaler therapy.

There are a number of reasons why identifying obstructive sleep apnea in infants is difficult, but new research shows feeding dysfunction could be an early link.

Little is understood about the systemic markers of worsening COPD. Investigators have observed at least 3 novel pathways.

A new assessment shows risk reduction is even more significant among COPD patients who have smoked.

A six-month study shows the common OSA therapy could have long-term benefit for reducing eventual cardiovascular risk.

Treatment drug results in a significant reduction in severe exacerbations for patients with eosinophil ≥150 cells/µL.

An assessment of FF/UMEC/VI in a single inhaler show its benefit in respiratory function among COPD patients at 24 weeks.

A 52-week assessment shows patients of varying interleukin serum levels equally benefitted from the TSLP inhibitor.

New trial testing vitamin D supplementation in pediatric asthma patients was stopped early because of ineffective data.

New ATS findings show the IL-5 inhibitor has sustained and oftentimes improved benefit in patients from 6 months to 12.

Dr. Ian Pavord discusses new meta-analyses of dupilumab planned for ATS 2020 on the DocTalk podcast.

When compared to placebo, benralizumab results in a significantly improved asthma exacerbation rates.